GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis,…
BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer,…